Upjohn’s Colestid
Executive Summary
Supplemental NDA for regression of atherosclerosis indication approved Dec. 18. The clinical pharmacology section of the package insert will now state that "intensive lipid-lowering combination therapy significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lessions."